| abstract |
The present application presents novel peptide inhibitors of beta amyloid cleavage enzyme, capable to permeate the blood-brain barrier and with no cytotoxic effects. Additionally, this application relates to a new methodology to inhibit BACE1 with peptidergic compounds. The peptides are incorporated in pharmaceutical compositions and applied in the treatment of Alzheimer's disease and in other neurological disorders such as Parkinson's disease, Vascular Dementia, Dementia with Lewy bodies, Amyotrophic Lateral Sclerosis, Down's Syndrome, head trauma, and stroke. |